http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-107951618-B

Outgoing Links

Predicate Object
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61F9-0008
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-049
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/G02C7-021
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61F9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G02C7-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G02C7-02
filingDate 2017-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2019-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationDate 2019-10-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CN-107951618-B
titleOfInvention A kind of contact lenses for drug treatment fungal keratitis
abstract The invention discloses a kind of contact lenses for drug treatment fungal keratitis, its entirety is rendered as the contact lens (1) of spherical crown shape, it is mainly made of soft layer (7) and hard layer (8) two parts bonding superposition and thermoforming process processing, is also formed with microfluidic channel (3) and hollow cavity (4) in the inside of contact lens (1);Wherein, hollow cavity (4) is for storing liquid medicine (5);Microfluidic channel (3) is for conveying liquid medicine (5), and one end is connected with hollow cavity (4), and the other end is communicated with liquid outlet (2), for being connected with contact lens (1) external world.The present invention is improved by material and eyeglass internal structure to contact lenses and corresponding technique, guarantee the contact lenses under the premise of not affecting vision, using contact lenses as drug delivery system, the defects of capable of effectively overcoming traditional methods of administration that can not ensure continued therapy effect and poor bioavailability.
priorityDate 2017-12-08-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isCitedBy http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10031348-B2
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5280965
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID410031093
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID71616
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419534914
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419590486
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419535690
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8027
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5284447
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID3365
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419505877

Total number of triples: 25.